Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 11/20 | 0.53 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.49 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 7/20 | 0.45 |
| ▸ | RORB | Q92753 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1340183 | 0.87 | BCAT2 (0.51) | PTGS1BCAT2MAPK14PTGS2 | |
| SCHEMBL27353967 | 0.85 | BCAT2 (0.69) | PTGS1BCAT2MAPK14PTGS2 | |
| SCHEMBL10333638 | 0.81 | BCAT2 (0.53) | PTGS1BCAT2RORB | |
| SCHEMBL9121778 | 0.80 | BCAT2 (0.72) | BCAT2RORB | |
| SCHEMBL3157739 | 0.78 | PTGS2 (0.51) | BCAT2PTGS2RORB | |
| SCHEMBL28228755 | 0.77 | PRKCZ (0.61) | PTGS1MAPK14 | |
| SCHEMBL11278816 | 0.77 | ESR1 (0.44) | — | |
| SCHEMBL3848295 | 0.77 | BCAT2 (0.45) | PTGS1BCAT2RORB | |
| SCHEMBL11705354 | 0.77 | BCAT2 (0.45) | PTGS1BCAT2RORB | |
| SCHEMBL1942722 | 0.77 | RORB (0.45) | PTGS1BCAT2RORB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8779168-B2 | Lactone compounds and materials made therefrom | TRANSITIONS OPTICAL, INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-20120157677-A1 | LACTONE COMPOUNDS AND MATERIALS MADE THEREFROM | TRANSITIONS OPTICAL INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20030207889-A1 | Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity | OWEN DAVID ALAN (GB) | 2003-11-06 | — | — | US | disclosed |
| US-6566384-B1 | For therapy of cancer, inflammation and inflammatory diseases, tissue degeneration, periodontal disease, ophthalmological disease, dermatological disorders, fever, cardiovascular effects, haemorrhage, coagulation and acute phase response | DARWIN DISCOVERY LTD. (GB) | 2003-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157677-A1 | LACTONE COMPOUNDS AND MATERIALS MADE THEREFROM | LSS, DCXR, NISCH | PTGS1 68/4885BCAT2 1401/4885MAPK14 4060/4885 |
| US-20030207889-A1 | Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity | MMP13, MMP2, MMP9 | PTGS1 93/4885BCAT2 342/4885MAPK14 997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.